SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.

Shandong Buchang Pharmaceuticals Co., Ltd.

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
16.50 ^CNY	0.00%		+0.73%	+5.50%

Dec. 29	Buchang Pharmaceuticals Taps Medispec to Distribute Anemia Drug in Malaysia	MT
Dec. 18	Buchang Pharmaceuticals Withdraws Marketing Application for Diabetes Drug	MT

Buchang Pharma Provides 80 Million Yuan Guarantee for Subsidiary Loan

Published on 11/27/2025 at 10:17 pm EST - Modified on 11/27/2025 at 10:33 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shandong Buchang Pharmaceuticals Co., Ltd.

Dec. 29	Buchang Pharmaceuticals Taps Medispec to Distribute Anemia Drug in Malaysia	MT
Dec. 18	Buchang Pharmaceuticals Withdraws Marketing Application for Diabetes Drug	MT
Dec. 10	Shandong Buchang Pharmaceuticals to Invest 510,000 Yuan in Zhuhai JV	MT
Dec. 02	Buchang Pharma Modifies Shaanxi Drug Manufacturing License	MT
Nov. 27	Buchang Pharma Signs Contract for Clinical Trial of Traditional Chinese Drug	MT
Nov. 27	Buchang Pharma Gets Regulatory Approval for Drug Manufacturing License Changes	MT
Nov. 27	Buchang Pharma Provides 80 Million Yuan Guarantee for Subsidiary Loan	MT
Nov. 26	Buchang Pharma Transfers Key Drug Clinical Development to Subsidiary	MT
Nov. 18	Shandong Buchang Pharmaceuticals Unit to Invest in Biotech JV	MT
25-10-29	Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-28	Jinan Buchang Shengyuan Medical Equipment Co., Ltd. announced that it expects to receive CNY 3 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd.	CI
25-10-17	Shandong Buchang Pharmaceuticals Unit Signs 11-Million-Yuan Technical Service Contract	MT
25-10-14	Buchang Pharmaceuticals Gets Nod for Registration of Ibuprofen Capsules	MT
25-09-30	Regulator OK's Revision in Shandong Buchang Pharmaceuticals' Drug Production License	MT
25-09-23	Buchang Pharma Gets Approval for Contract Manufacturing for Two Drugs; Shares Down 3%	MT
25-09-09	Shandong Buchang Pharmaceuticals Gets Contract Manufacturing License	MT
25-08-27	Shandong Buchang Pharmaceuticals H1 net profit up 171.2% Y/Y	RE
25-08-27	Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-21	Shandong Buchang Pharmaceuticals Unit Signs Technology Transfer Deal with Hospital for Kidney Treatment	MT
25-08-14	Shandong Buchang Pharmaceuticals Subsidiary Gets Regulatory Nod for Drug Production Adjustments	MT
25-08-07	Buchang Pharma Authorizes Goodfellow As Philippine Distributor for Efparepoetin Alfa for Injection	MT
25-07-31	Buchang Pharmaceuticals' Unit Gets Nod to Amend Production Scope in License	MT
25-07-14	Shandong Buchang Pharmaceuticals sees H1 net profit up 110.9-205.9% Y/Y	RE
25-07-01	Buchang Pharmaceuticals' Unit Gets Registration Certificate for Lacosamide Injection	MT
25-06-20	Shandong Buchang Pharmaceuticals Co., Ltd. agreed to acquire an additional 8.50% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) for CNY 0.	CI

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

603858: Dynamic Chart

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Employees

7,689

Sector

Pharmaceuticals

Calendar

Apr. 23 - Q1 2026 Earnings Release (Projected)

More about the company